PTPRC and acute myeloid leukemia: On day 32, the combination of ONC213 and venetoclax significantly reduced the number of circulating bulk AML cells (CD45+) compared to the control and monotherapy treated mice and significantly reduced circulating AML stem cells compared to control and venetoclax treated mice (Fig. 3E&F).